# Safety and Tolerability of Varying Load and Dose of ISIS 301012 in People With Elevated LDL-cholesterol Levels

> **NCT00216463** · PHASE2 · COMPLETED · sponsor: **Kastle Therapeutics, LLC** · enrollment: 50 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** ISIS 301012 or Placebo
- **DRUG:** ISIS 301012 or Placebo
- **DRUG:** ISIS 301012 or Placebo
- **DRUG:** ISIS 301012 or Placebo
- **DRUG:** ISIS 301012 or Placebo

## Key facts

- **NCT ID:** NCT00216463
- **Lead sponsor:** Kastle Therapeutics, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2007-03
- **Final completion:** 2007-08
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2016-08-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00216463

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00216463, "Safety and Tolerability of Varying Load and Dose of ISIS 301012 in People With Elevated LDL-cholesterol Levels". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00216463. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*